Back to Search
Start Over
Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicentre retrospective cohort in daily practice.
- Source :
-
Journal of the European Academy of Dermatology & Venereology . Dec2022, Vol. 36 Issue 12, p2423-2429. 7p. - Publication Year :
- 2022
-
Abstract
- Background: Dupilumab is the first biotherapy available for the treatment of moderate‐to‐severe childhood atopic dermatitis (AD). Objective: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. Methods: Patients aged 6–11, who had received a first dose of dupilumab, were included in this multicentre retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial. Results: Eighty patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; P < 0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; P < 0.0001). Conjunctivitis was observed in 11.3% (n = 9/80); three patients experienced dupilumab facial redness (DFR); 17.5% (n = 14/80) reported injection site reactions; 6.3% (n = 5/80) discontinued treatment. 61.2% (n = 49/80) children were ineligible in the phase 3 trial. Limitations: There is no control group. Because it was a real life study based on information from patient medical records in a French multicentre cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information. Conclusion: These real‐life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DUPILUMAB
*ATOPIC dermatitis
*CLINICAL trials
*IMMUNOGLOBULIN A
Subjects
Details
- Language :
- English
- ISSN :
- 09269959
- Volume :
- 36
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- Journal of the European Academy of Dermatology & Venereology
- Publication Type :
- Academic Journal
- Accession number :
- 160200213
- Full Text :
- https://doi.org/10.1111/jdv.18450